mb core glp-1 Benefits Beyond Weight Loss LifeVantage Announces International Launch of

This shift in fat distribution carries particular health implications, as visceral adiposity is associated with increased cardiovascular risk, type 2 diabetes, and metabolic syndrome

Hims & Hers GLP-1 injectable not evaluated by FDA, class action claims Hims & Hers compounded semaglutide products have not been meaningfully tested for safety or effectiveness or evaluated by the U.S

Ocular risks: recent matched cohort studies have suggested a potential association between semaglutide prescriptions and an increased risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) (Hazard Ratio 4.28, with inter-study estimates ranging from 4 to 7)

CVS Health, parent company of Hartford-based health insurer Aetna, said high prices set by GLP-1 drug manufacturers remain the biggest obstacle to broader access

GLP-1 receptor agonists should not be combined with DPP-4 inhibitors , as both act on the incretin pathway